Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Retaron is a dietary supplement, specifically classified as a Food for Special Medical Purposes (FSMP), developed for the dietary management of age-related macular degeneration (AMD). It is characterized by its inclusion of Aronia berry (chokeberry) extract, which provides a high concentration of anthocyanins and other polyphenols that exert potent antioxidant and anti-inflammatory effects within the ocular tissues. In addition to Aronia extract, Retaron contains the carotenoids lutein and zeaxanthin, which accumulate in the macula to filter high-energy blue light and neutralize singlet oxygen. The formulation is further supported by essential trace elements (zinc and selenium) and vitamins (C and E) that serve as cofactors for endogenous antioxidant enzymes or directly scavenge free radicals. Together, these components aim to slow the progression of AMD by protecting retinal pigment epithelial cells and photoreceptors from oxidative stress-induced damage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Retaron.